In our previous OpACIN-neo trial testing different dosing schedules of neoadjuvant ipilimumab + nivolumab in stage III melanoma, we identified the 10-gene IFN-γ signature (Ayers et al., 2017) as a predictive baseline biomarker for pathologic response (Rozeman et al., 2021). Here, IFNG is linked to melanoma.